Go Pro
→ The $15 Gold Fund That Pays Up to $1,152/Month (From Investors Alley) (Ad)tc pixel
NASDAQ:CTSO

Cytosorbents Q3 2024 Earnings Report

Cytosorbents logo
$0.40 +0.04 (+10.38%)
Closing price 08/14/2026 04:00 PM Eastern
Extended Trading
$0.40 +0.00 (+0.03%)
As of 08/14/2026 07:08 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Cytosorbents EPS Results

Actual EPS
-$0.08
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Cytosorbents Revenue Results

Actual Revenue
$8.61 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Cytosorbents Announcement Details

Quarter
Q3 2024
Date
1/3/2025
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Cytosorbents Earnings Headlines

Cytosorbents (CTSO) Q2 2026 Earnings Call Transcript
August 13 at 10:12 PM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/cytosorbents-ctso-q2-2026-earnings-232956630.html
Q3 EPS Estimates for Cytosorbents Lowered by HC Wainwright
August 13 at 1:58 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30957445
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying out up to $1,152 a month to regular investors - no mining stocks, no options, no physical metal required. Chief Income Strategist Tim Plaehn calls it a breakthrough strategy that transforms gold's rally into reliable monthly payouts. The next distribution is just days away.tc pixel
 |  Investors Alley (Ad)
HC Wainwright Has Weak Forecast for Cytosorbents Q1 Earnings
August 10, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30951455
Cytosorbents Corporation (CTSO) Q2 2026 Earnings Call Transcript
August 7, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4932773-cytosorbents-corporation-ctso-q2-2026-earnings-call-transcript
CytoSorbents Reports Second Quarter 2026 Financial Results, Recent Business Highlights, and Regulatory Update
August 6, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/cytosorbents-reports-second-quarter-2026-financial-results-recent-business-highlights-and-regulatory-update-302845431.html
See More Cytosorbents Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Cytosorbents? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cytosorbents and other key companies, straight to your email.

About Cytosorbents

Cytosorbents (NASDAQ:CTSO), founded in 2011 and headquartered in Princeton, New Jersey, is a medical device company focused on critical care and extracorporeal blood purification. The company’s flagship product, CytoSorb, is a hemoadsorption cartridge designed to remove excessive inflammatory mediators such as cytokines, bilirubin and myoglobin from a patient’s blood. By targeting the molecular drivers of hyperinflammation, CytoSorb is intended to stabilize patients undergoing septic shock, cardiac surgery, trauma and organ failure.

CytoSorb has secured regulatory clearance in Europe (CE mark) and is available in more than 65 countries, with a growing presence in Asia, the Middle East and Latin America. In the United States, the device received Emergency Use Authorization from the U.S. Food and Drug Administration for treatment of critically ill COVID-19 patients exhibiting a cytokine storm. Clinicians integrate CytoSorb into standard extracorporeal circuits such as continuous renal replacement therapy (CRRT) and cardiopulmonary bypass to optimize blood purification protocols in intensive care units.

Beyond its core sorbent technology, Cytosorbents is advancing a pipeline of next-generation products aimed at drug overdose management and vaccine adjuvant development. The company’s R&D efforts leverage proprietary polymer bead platforms to broaden the applications of hemoadsorption in pharmaceutical safety and immunotherapy. With a global sales and distribution network and strategic partnerships in key markets, Cytosorbents continues to expand clinical evidence to support broader adoption of its blood purification solutions.

View Cytosorbents Profile
Earnings Tools